Volume 17, Issue 3, March 2020 - First Report Managed Care
03/31/2020
With more therapies than ever moving through the pipeline, developers and payers are looking at new ways to lower costs while ramping up gene therapy production.
With more therapies than ever moving through the pipeline, developers and payers are looking at new ways to lower costs while ramping up gene therapy production.
With more therapies than ever...
03/31/2020
First Report Managed Care
Department
Formulary Frontlines®
03/31/2020
RA has a significant negative impact on the ability to perform daily activities and on health-related quality of life, conferring a substantial health care and economic burden. Costs attributable to RA are expected to further increase as the...
RA has a significant negative impact on the ability to perform daily activities and on health-related quality of life, conferring a substantial health care and economic burden. Costs attributable to RA are expected to further increase as the...
RA has a significant negative...
03/31/2020
First Report Managed Care
News Connection
03/31/2020
Aetna will be partnering with Atlanta-based Emory Healthcare and Northside Hospital System to provide a fully insured and self-insured health care options for employers.
Aetna will be partnering with Atlanta-based Emory Healthcare and Northside Hospital System to provide a fully insured and self-insured health care options for employers.
Aetna will be partnering with...
03/31/2020
First Report Managed Care
News Connection
03/31/2020
Changes in patient-centered medical home (PCMH) implementation had no consistent association with changes in high cost health care utilization, according to a study results published in JAMA Network Open.
Changes in patient-centered medical home (PCMH) implementation had no consistent association with changes in high cost health care utilization, according to a study results published in JAMA Network Open.
Changes in patient-centered...
03/31/2020
First Report Managed Care
News Connection
03/31/2020
From 1999 to 2018, the United States pharmaceutical and health product industry spent $4.7 billion on lobbying expenditures and campaign contributions, according to a recent JAMA Internal Medicine study.
From 1999 to 2018, the United States pharmaceutical and health product industry spent $4.7 billion on lobbying expenditures and campaign contributions, according to a recent JAMA Internal Medicine study.
From 1999 to 2018, the United...
03/31/2020
First Report Managed Care
News Connection
03/31/2020
Humana is launching a new value-based care payment initiative that will focus on social determinants of health to help clinicians better address nonmedical health risk factors.
Humana is launching a new value-based care payment initiative that will focus on social determinants of health to help clinicians better address nonmedical health risk factors.
Humana is launching a new...
03/31/2020
First Report Managed Care
News Connection
03/31/2020
As the number of US adults reaching retirement age continues to grow, researchers of a recent JAMA Network Open study sought to measure the association between high health insurance costs and potential avoidance of medical care, and found a...
As the number of US adults reaching retirement age continues to grow, researchers of a recent JAMA Network Open study sought to measure the association between high health insurance costs and potential avoidance of medical care, and found a...
As the number of US adults...
03/31/2020
First Report Managed Care
News Connection
03/31/2020
The Institute for Clinical and Economic Review (ICER) announced a new partnership with health care technology company Aetion in a continued effort to expand its use of real-world evidence (RWE) in patient data.
The Institute for Clinical and Economic Review (ICER) announced a new partnership with health care technology company Aetion in a continued effort to expand its use of real-world evidence (RWE) in patient data.
The Institute for Clinical and...
03/31/2020
First Report Managed Care
03/31/2020
In our second installment of the expert roundtable on drug pricing, our experts weigh in on what progress can be made in 2020, when it will impact managed care stakeholders, and what that impact will be.
In our second installment of the expert roundtable on drug pricing, our experts weigh in on what progress can be made in 2020, when it will impact managed care stakeholders, and what that impact will be.
In our second installment of the...
03/31/2020
First Report Managed Care
